DRMAW
Dermata Therapeutics Inc. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-2.16
Beta
0.50
52W High
$0.03
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dermata Therapeutics Inc. Warrant
Dermata Therapeutics Inc. is a pioneering biotechnology company focused on the development of cutting-edge therapies for dermatological conditions, with a particular emphasis on addressing significant unmet medical needs. Utilizing its proprietary platform, Dermata is advancing innovative treatments aimed at acne and other skin disorders, positioning itself strategically within a market characterized by rising disease prevalence. With a robust pipeline of product candidates and a commitment to transforming patient care, Dermata presents compelling growth prospects that may appeal to institutional investors seeking opportunities in the biotech sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-4.09M |
| Operating Margin | 0.00% |
| Return on Equity | -194.20% |
| Return on Assets | -85.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.34 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $2.93M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
66.85%
HV 20-Day
233.36%
HV 30-Day
195.19%
HV 60-Day
179.27%
HV Rank
—
Volatility is currently contracting
Data last updated: 4/14/2026